Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Discovering New Benefits From Old Drugs With Big Data-Promise for Parkinson Disease.

Olsen AL, Riise T, Scherzer CR.

JAMA Neurol. 2018 Apr 23. doi: 10.1001/jamaneurol.2018.0345. [Epub ahead of print] No abstract available.

PMID:
29710184
2.

β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.

Mittal S, Bjørnevik K, Im DS, Flierl A, Dong X, Locascio JJ, Abo KM, Long E, Jin M, Xu B, Xiang YK, Rochet JC, Engeland A, Rizzu P, Heutink P, Bartels T, Selkoe DJ, Caldarone BJ, Glicksman MA, Khurana V, Schüle B, Park DS, Riise T, Scherzer CR.

Science. 2017 Sep 1;357(6354):891-898. doi: 10.1126/science.aaf3934.

PMID:
28860381
3.

Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.

Gwinn K, David KK, Swanson-Fischer C, Albin R, Hillaire-Clarke CS, Sieber BA, Lungu C, Bowman FD, Alcalay RN, Babcock D, Dawson TM, Dewey RB Jr, Foroud T, German D, Huang X, Petyuk V, Potashkin JA, Saunders-Pullman R, Sutherland M, Walt DR, West AB, Zhang J, Chen-Plotkin A, Scherzer CR, Vaillancourt DE, Rosenthal LS.

Biomark Med. 2017 May;11(6):451-473. doi: 10.2217/bmm-2016-0370. Epub 2017 Jun 23.

PMID:
28644039
4.

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.

Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR; HBS; CamPaIGN; PICNICS; PROPARK; PSG; DIGPD; PDBP.

Lancet Neurol. 2017 Aug;16(8):620-629. doi: 10.1016/S1474-4422(17)30122-9. Epub 2017 Jun 16.

PMID:
28629879
5.

Defining the contribution of neuroinflammation to Parkinson's disease in humanized immune system mice.

Manocha GD, Floden AM, Puig KL, Nagamoto-Combs K, Scherzer CR, Combs CK.

Mol Neurodegener. 2017 Feb 14;12(1):17. doi: 10.1186/s13024-017-0158-z.

6.

Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.

Liu G, Boot B, Locascio JJ, Jansen IE, Winder-Rhodes S, Eberly S, Elbaz A, Brice A, Ravina B, van Hilten JJ, Cormier-Dequaire F, Corvol JC, Barker RA, Heutink P, Marinus J, Williams-Gray CH, Scherzer CR; International Genetics of Parkinson Disease Progression (IGPP) Consortium.

Ann Neurol. 2016 Nov;80(5):674-685. doi: 10.1002/ana.24781.

7.

Identification of genetic modifiers of age-at-onset for familial Parkinson's disease.

Hill-Burns EM, Ross OA, Wissemann WT, Soto-Ortolaza AI, Zareparsi S, Siuda J, Lynch T, Wszolek ZK, Silburn PA, Mellick GD, Ritz B, Scherzer CR, Zabetian CP, Factor SA, Breheny PJ, Payami H.

Hum Mol Genet. 2016 Sep 1;25(17):3849-3862. doi: 10.1093/hmg/ddw206. Epub 2016 Jul 11.

8.

Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients.

Takeda S, Commins C, DeVos SL, Nobuhara CK, Wegmann S, Roe AD, Costantino I, Fan Z, Nicholls SB, Sherman AE, Trisini Lipsanopoulos AT, Scherzer CR, Carlson GA, Pitstick R, Peskind ER, Raskind MA, Li G, Montine TJ, Frosch MP, Hyman BT.

Ann Neurol. 2016 Sep;80(3):355-67. doi: 10.1002/ana.24716. Epub 2016 Aug 3.

9.

A Feed-Forward Circuit of Endogenous PGC-1α and Estrogen Related Receptor α Regulates the Neuronal Electron Transport Chain.

Bakshi R, Mittal S, Liao Z, Scherzer CR.

Parkinsons Dis. 2016;2016:2405176. doi: 10.1155/2016/2405176. Epub 2016 Mar 3.

10.

α-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities.

Lööv C, Scherzer CR, Hyman BT, Breakefield XO, Ingelsson M.

Cell Mol Neurobiol. 2016 Apr;36(3):437-48. doi: 10.1007/s10571-015-0317-0. Epub 2016 Mar 18. Review.

PMID:
26993503
11.

The NINDS Parkinson's disease biomarkers program.

Rosenthal LS, Drake D, Alcalay RN, Babcock D, Bowman FD, Chen-Plotkin A, Dawson TM, Dewey RB Jr, German DC, Huang X, Landin B, McAuliffe M, Petyuk VA, Scherzer CR, Hillaire-Clarke CS, Sieber BA, Sutherland M, Tarn C, West A, Vaillancourt D, Zhang J, Gwinn K; PDBP consortium.

Mov Disord. 2016 Jun;31(6):915-23. doi: 10.1002/mds.26438. Epub 2015 Oct 7.

12.

Aging, the Central Nervous System, and Mobility in Older Adults: Neural Mechanisms of Mobility Impairment.

Sorond FA, Cruz-Almeida Y, Clark DJ, Viswanathan A, Scherzer CR, De Jager P, Csiszar A, Laurienti PJ, Hausdorff JM, Chen WG, Ferrucci L, Rosano C, Studenski SA, Black SE, Lipsitz LA.

J Gerontol A Biol Sci Med Sci. 2015 Dec;70(12):1526-32. doi: 10.1093/gerona/glv130. Epub 2015 Sep 18.

13.

Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease.

Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, Selkoe DJ, Oakes D, Shoulson I, Dong X, Marek K, Zheng B, Ivinson A, Hyman BT, Growdon JH, Sudarsky LR, Schlossmacher MG, Ravina B, Scherzer CR.

Brain. 2015 Sep;138(Pt 9):2659-71. doi: 10.1093/brain/awv202. Epub 2015 Jul 28.

14.

High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types.

Doss S, Wandinger KP, Hyman BT, Panzer JA, Synofzik M, Dickerson B, Mollenhauer B, Scherzer CR, Ivinson AJ, Finke C, Schöls L, Müller Vom Hagen J, Trenkwalder C, Jahn H, Höltje M, Biswal BB, Harms L, Ruprecht K, Buchert R, Höglinger GU, Oertel WH, Unger MM, Körtvélyessy P, Bittner D, Priller J, Spruth EJ, Paul F, Meisel A, Lynch DR, Dirnagl U, Endres M, Teegen B, Probst C, Komorowski L, Stöcker W, Dalmau J, Prüss H.

Ann Clin Transl Neurol. 2014 Oct;1(10):822-32. doi: 10.1002/acn3.120. Epub 2014 Oct 18.

15.

Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.

Santiago JA, Scherzer CR, Potashkin JA.

PLoS One. 2014 Oct 3;9(10):e109042. doi: 10.1371/journal.pone.0109042. eCollection 2014.

16.

Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker study.

Mehanna R, Scherzer CR, Ding H, Locascio JJ.

Neurology. 2014 May 6;82(18):1666; discussion 1666. doi: 10.1212/01.wnl.0000449750.81263.7d. No abstract available.

PMID:
24799519
17.

Motor impulsivity in Parkinson disease: associations with COMT and DRD2 polymorphisms.

Ziegler DA, Ashourian P, Wonderlick JS, Sarokhan AK, Prelec D, Scherzer CR, Corkin S.

Scand J Psychol. 2014 Jun;55(3):278-86. doi: 10.1111/sjop.12113. Epub 2014 Apr 21.

18.

MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration.

Cebrián C, Zucca FA, Mauri P, Steinbeck JA, Studer L, Scherzer CR, Kanter E, Budhu S, Mandelbaum J, Vonsattel JP, Zecca L, Loike JD, Sulzer D.

Nat Commun. 2014 Apr 16;5:3633. doi: 10.1038/ncomms4633.

19.

Metallothioneins as dynamic markers for brain disease in lysosomal disorders.

Cesani M, Cavalca E, Macco R, Leoncini G, Terreni MR, Lorioli L, Furlan R, Comi G, Doglioni C, Zacchetti D, Sessa M, Scherzer CR, Biffi A.

Ann Neurol. 2014 Jan;75(1):127-37. doi: 10.1002/ana.24053.

20.

Specific splice variants are associated with Parkinson's disease.

Santiago JA, Scherzer CR; Harvard Biomarker Study, Potashkin JA.

Mov Disord. 2013 Oct;28(12):1724-7. doi: 10.1002/mds.25635. Epub 2013 Sep 20.

Supplemental Content

Loading ...
Support Center